Aetiology

Monogenic (Mendelian): ~75–80%, KCNQ1, KCNH2 and SCN5A account for ~90% of genotyped cases^[1]

Acquired: acquired long QT (QT-prolonging drugs, hypokalaemia/hypomagnesaemia, bradycardia) is a separate, reversible entity to exclude^[1]

Complex (likely polygenic): ~20–25% gene-elusive, partly reflecting polygenic QT modulation^[8]

Genetics

Inheritance: Autosomal dominant (Romano-Ward syndrome) in genotype-positive families, with incomplete and variable penetrance: many carriers have a QTc in the normal range^[7]; rare autosomal recessive (Jervell-Lange-Nielsen syndrome with congenital deafness, homozygous/compound heterozygous KCNQ1 or KCNE1 variants, nearly 100% penetrance).

Genetic yield: ~75% with comprehensive testing^[1]. Up to 25% are gene-elusive; a negative test does not lower the threshold for treatment, and management is guided by phenotype: QTc, symptoms, triggers and family history (Asatryan et al 2024, Circ Arrhythm Electrophysiol)^[8]

ClinGen-validated genes, with genotype-specific management (Zhu et al 2024, Schwartz & Crotti NEJM 2025)^[7]^[2]^[9]

Gene / subtype	% of genotype- positive^[12]^[2]	Channel / mechanism	Arrhythmic triggers	ECG pattern	Key management points
KCNQ1LQT1	43–50%	IKs loss-of-function (K⁺)	Exercise, swimming (adrenergic)	Broad-based T wave	Beta-blockers most effective; nadolol preferred; restrict competitive swimming
KCNH2LQT2	32–40%	IKr loss-of-function (K⁺)	Auditory triggers, emotion, postpartum	Notched/bifid T wave	Higher risk in females; avoid alarm clocks; K⁺ supplementation; beta-blockers effective
SCN5ALQT3	10–13%	INa gain-of-function (Na⁺ delayed inactivation)	Rest/sleep, bradycardia	Long isoelectric ST segment	Mexiletine (off-label): shortens QTc, reduces events; beta-blockers less effective; pacemaker in selected cases
CALM1/2/3Calmodulinopathy	Rare (not tested)	Calmodulin (impaired Ca²⁺-channel inactivation)	Variable; often de novo	Extreme QTc prolongation	Severe early-onset, very high arrhythmic risk; early ICD; consider LCSD; flecainide may have a role; specialist centre; neurodevelopmental features
TRDN–	Rare (not tested)	Triadin; autosomal recessive	Exercise-triggered	T-wave abnormalities at rest	–
CACNA1CLQT8 (Timothy)	Rare (not tested)	ICaL gain-of-function (Ca²⁺)	–	–	Multiorgan syndrome: ASD, autism, syndactyly; very rare

% column: ranges run from a referral cohort to the approximate shares in a 2025 review (about 50%, 40% and 10%)^[2]. In the referral cohort, 903 of 2,500 unrelated patients referred for a five-gene test (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2) carried a putative LQTS variant; 9% carried more than one variant and are not counted in the gene rows, and calmodulin, triadin and CACNA1C were not tested^[12]. Across cohorts, the three main genes account for about 90% of genotype-positive LQTS^[1].

Gene-elusive LQTS (~11–25%): Multiple mechanisms, polygenic risk score contribution, environmental QTc modulators, exercise-induced repolarisation abnormalities, new causal genes not yet identified, or variant reclassification over time. The group is heterogeneous and also contains acquired QT prolongation, polygenic QT variation and misdiagnosis, so do not dismiss LQTS on a negative test and do not treat it as a single entity: where the clinical diagnosis is secure (QTc ≥480 ms on repeated ECGs, or Schwartz score >3), manage on phenotype as for genotype-positive disease. Referral to a specialised cardiogenetic clinic is recommended (Asatryan et al 2024)^[8].

Modifier genes: Common variants modulate QTc and arrhythmic risk in individual patients, polygenic risk scores can refine risk stratification beyond the primary pathogenic variant (Schwartz & Crotti, NEJM 2025).

Prevalence

Estimated prevalence 1 in 2,000 to 1 in 2,500 in the general population; actual prevalence may be higher due to variable penetrance, silent mutation carriers, and under-diagnosis^[7]

More common in females for arrhythmic events (especially LQT2); variable penetrance, many carriers have QTc within normal range

LQTS is an important cause of autopsy-negative sudden unexplained death in the young, though reported proportions vary widely by population and ascertainment^[7]

Autosomal dominant forms (Romano-Ward): each child of a carrier has a 50% probability of inheriting the pathogenic variant; most LQTS variants are inherited, so parents and siblings are also at substantial risk and cascade genetic screening is essential^[7]

Three definitive principal genes account for the large majority of genotype-positive LQTS: LQT1 (KCNQ1), LQT2 (KCNH2), and LQT3 (SCN5A) together account for ~80–90% of genotype-positive cases. A number of other genes have historically been reported as rare/syndromic causes or proposed modifiers, but many of these historical associations are disputed or lack definitive gene-disease validation, an unqualified "at least 17 genes" count should not be presented as if all carry equal, definitive evidence^[7]

Diagnostic Criteria

Diagnostic criteria (ESC 2022)^[1]

LQTS is diagnosed (Class I) if any of the following:

QTc ≥480 ms on repeated 12-lead ECGs, with or without symptoms, in the absence of secondary causes
LQTS (Schwartz) score >3
Pathogenic LQTS variant identified, irrespective of QT duration

LQTS should be considered (Class IIa) if:

QTc ≥460 ms and <480 ms on repeated ECGs with arrhythmic syncope, in the absence of secondary causes^[1]

Not recommended (Class III):

Routine epinephrine challenge testing
Invasive electrophysiological study

Measure QT manually in appropriate leads on repeated ECGs; Bazett's formula (QTc = QT/√RR) underlies many diagnostic thresholds, but interpret cautiously at high or low heart rates and consider Fridericia or Framingham for borderline values

Modified Schwartz score^[1]Points for the criterion ‘score >3’ above

Criterion	Points
ECG Findings
QTc ≥480 ms	3.5
QTc 460-479 ms	2
QTc 450-459 ms (males only)	1
QTc ≥480 ms at the 4th minute of recovery from an exercise test	1
Torsades de pointes	2
T-wave alternans	1
Notched T-wave in ≥3 leads	1
Low heart rate for age	0.5
Clinical History
Syncope with stress/emotion	2
Syncope without stress	1
Family History
Family member(s) with definite LQTS	1
Unexplained SCD <30 years in a first-degree relative	0.5
Genetic Finding
Pathogenic variant	3.5

Interpretation: ≥3.5 = high probability; 1.5–3 = intermediate; ≤1 = low probability. Torsades de pointes and syncope are mutually exclusive, and one family member cannot be counted under both family-history items^[3]

Gene-Elusive LQTS: Key Pitfalls (Asatryan et al, Circ Arrhythm Electrophysiol 2024)^[8]

11–25% of LQTS patients have negative genetic testing. Do not dismiss LQTS on a negative test: where the clinical diagnosis is secure (QTc ≥480 ms on repeated ECGs, or Schwartz score >3), manage on phenotype, i.e. QTc, symptoms, triggers and family history, as for genotype-positive disease.

Most common error: Including U waves in QTc measurement → overestimation of borderline QTc. Anterior T-wave inversion in ~20% of LQTS, can mislead.
Exercise testing: the diagnostic score awards 1 point for a QTc ≥480 ms at the 4th minute of recovery^[1]. In asymptomatic first-degree relatives of genotyped probands, a lower 4-minute recovery cut-off of ≥445 ms, used together with the resting QTc, identified LQT1 and LQT2 carriers with 92% sensitivity and 82% specificity in a validation cohort^[10]. A test done on beta-blockers is interpreted with caution; beta-blockers are not withheld for diagnostic purposes where LQTS is established or there has been syncope or arrhythmia, and any planned interruption is a specialist decision.
Do not reduce management intensity because genetics is negative, cascade ECG screening of all 1st-degree relatives still applies.
16% of patients referred to LQTS centres for second opinion ultimately did NOT have LQTS. Expert cardio-genetic review is essential.

Diagnosis

Clinical Presentation:

Often asymptomatic - diagnosed on screening or incidental ECG
Syncope (often misdiagnosed as seizure)
Cardiac arrest / sudden death
Palpitations (may precede syncope)

Genotype-specific triggers:

LQT1: Exercise (especially swimming)
LQT2: Auditory triggers (alarm clock, phone), emotions, postpartum
LQT3: Rest, sleep

Important: Exclude secondary causes before diagnosing congenital LQTS (electrolyte abnormalities, medications)

Investigations

First-line:

Resting 12-lead ECG (QTc measurement, T-wave morphology)
Repeat ECGs (QTc can vary)
24-hour Holter monitoring (QTc during sleep, T-wave alternans)
Exercise stress test (QTc during recovery, paradoxical QT prolongation in LQT1)

Provocation tests (specialist centres):

Epinephrine challenge test (can unmask LQTS, particularly LQT1)

Genetic testing:

Recommended in all with high clinical suspicion
Enables genotype-specific management
Facilitates family cascade screening

Exclude secondary causes of QT prolongation:

Medications (check www.crediblemeds.org)
Electrolyte abnormalities (K+, Mg2+, Ca2+)
Hypothyroidism, bradycardia, structural heart disease

Treatments

1. General measures:

Avoid QT-prolonging drugs (check www.crediblemeds.org)
Maintain normal electrolytes (target K⁺ 4–5 mmol/L; 4.5–5 mmol/L in LQT2, where IKr current is hypersensitive to hypokalaemia); oral KCl supplements or dietary advice, IV replacement if hospitalised
Avoid loud alarms/sudden awakening (LQT2)
Genotype-specific restrictions (avoid swimming in LQT1)
Clinical expert evaluation for competitive sports (see Exercise tab)
Avoid hypokalaemia, hypomagnesaemia, high-dose diuretics, sudden bradycardia

2. Medical therapy:

Beta-blockers (Class I, documented QT prolongation with or without symptoms; Class IIa, pathogenic variant with a normal QTc^[1]): Highly effective in LQT1/LQT2; less so in LQT3. Reassess annually (Schwartz & Crotti, NEJM 2025^[2]).
- Nadolol (preferred, long-acting, once/twice daily, consistent levels^[4]):
  - Start 40 mg once daily → target 80–160 mg once daily (up to 3 mg/kg/day in children)
  - UK: Available via SPECIALS / named patient import, arrange in advance through hospital pharmacy^[6]
  - Renally cleared, reduce dose if eGFR <50 ml/min; avoid if eGFR <30
- Propranolol (alternative, especially in children or if nadolol unavailable):
  - Start 20–40 mg two to three times daily → target 80–160 mg twice daily (total 160–320 mg/day)
  - Paediatric: 2–4 mg/kg/day in 3–4 divided doses
  - Short-acting formulation available; longer-acting (LA/SR) preferred for compliance
- Bisoprolol (alternative if nadolol/propranolol not tolerated): 2.5–10 mg once daily, note less evidence specifically for LQTS
Mexiletine (LQT3 with prolonged QT, Class I, off-label^[1]): Sodium channel blocker, reduces persistent INa, shortens QTc in SCN5A-positive LQT3.
- Start 50–100 mg three times daily with food → target 150–200 mg three times daily
- Maximum 900 mg/day; check QTc after dose changes (should shorten in LQT3)
- Monitor LFTs; avoid if significant hepatic impairment

3. Device therapy / surgery:

ICD: secondary prevention after cardiac arrest; primary prevention if syncope on beta-blockers or very high-risk features
Left cardiac sympathetic denervation (LCSD): for patients with recurrent events despite beta-blockers, or if ICD refused/contraindicated or beta-blockers ineffective

4. Acute management (torsades de pointes / electrical storm):

Haemodynamically unstable or sustained arrhythmia: advanced life support with external cardioversion/defibrillation; interrogate any ICD to exclude inappropriate therapy (Class I)^[1]
Sedation to reduce sympathetic tone (Class I)^[1]
IV magnesium with potassium supplementation (Class I)^[1]: magnesium sulfate 2 g IV over 10–15 min, repeated or followed by an infusion if TdP recurs; effective even when serum magnesium is normal. Keep K⁺ 4.5–5 mmol/L
Stop QT-prolonging drugs and correct precipitants (hypokalaemia, hypomagnesaemia, bradycardia)
Beta-blocker, non-selective preferred (Class I)^[1]: start or up-titrate; check adherence, as missed doses are a common trigger
Temporary pacing where bradycardia or post-extrasystolic pauses initiate TdP (Class I)^[1]
Isoprenaline is used to raise the heart rate in acquired (drug-induced) long QT only (Class I)^[1]; in congenital LQTS adrenergic stimulation is the trigger (especially LQT1/LQT2), so beta-blockade and pacing are used instead
Antiarrhythmic according to genotype (Class IIa)^[1]: in LQT3, sodium-channel blockade with mexiletine (Class I for LQT3 with prolonged QT)^[1]
Refractory storm: autonomic modulation, e.g. stellate ganglion block or LCSD (Class IIa); deep sedation/intubation (Class IIa)^[1]

Related Resources

Complications

Torsades de pointes: causing syncope, seizures, aborted cardiac arrest and sudden death, with genotype-specific triggers (LQT1 exertion and swimming, LQT2 auditory and postpartum, LQT3 rest and sleep)^[1]
Postpartum arrhythmia surge: particularly in LQT2
ICD-related complications: inappropriate shocks and lead failure over decades in young patients

Risk Stratification

High-risk features (consider ICD):

Cardiac arrest survivor (secondary prevention)
Syncope despite adequate beta-blocker therapy
Marked QTc prolongation, typically >500ms, which raises risk but is not on its own an indication for an ICD
LQT2 or LQT3 genotype with high-risk features
Female with LQT2 in postpartum period

These features should be integrated (with the risk calculator below and specialist shared decision-making) rather than treated individually as automatic ICD indications; beta-blockade and trigger avoidance remain the foundation of therapy.

ICD and LCSD:^[1]

Class I: ICD with beta-blockers after cardiac arrest
Class I: ICD for arrhythmic syncope or haemodynamically non-tolerated ventricular arrhythmia on beta-blockers and genotype-specific therapy
Class IIa: ICD or LCSD when symptomatic and beta-blockers or genotype-specific therapy are not tolerated or contraindicated
Class IIb: ICD when asymptomatic but high risk on the 1-2-3 LQTS Risk calculator, with genotype-specific therapy

Beta-blocker therapy indicated:

Documented QT prolongation, with or without symptoms (Class I); nadolol or propranolol preferred^[1]
Pathogenic variant with a normal QTc (Class IIa)^[1]

Risk modifiers:

LQT1: risk higher in boys during childhood and in women after adolescence (age- and sex-dependent); events common during exercise/swimming
LQT2: Female sex higher risk; postpartum period very high risk (continue beta-blockers)
LQT3: Male sex higher risk; events during sleep
QTc >500ms marks substantially higher risk across genotypes, though it is one factor among several rather than a standalone determinant

Risk calculator: the 1-2-3 LQTS Risk calculator estimates the 5-year risk of life-threatening arrhythmia from genotype (LQT1, LQT2 or LQT3) and QTc; estimating risk this way before starting therapy should be considered (Class IIa)^[1]

Pregnancy Management

mWHO class II–III or above: refer to a Pregnancy Heart Team before conception (see Pregnancy).

Pregnancy in LQTS - individualized risk assessment (2025 ESC pregnancy approach)

PRECONCEPTION COUNSELLING:

Risk stratification: genotype, symptom history, QTc and beta-blocker therapy all inform risk, but should be weighed together by a Pregnancy Heart Team rather than mapped onto a single fixed mWHO class^[5]. As a general pattern, LQT1 with no prior symptoms, QTc <500ms and established beta-blocker therapy tends to carry lower risk; LQT2, symptomatic disease, marked QTc prolongation or an ICD are associated with materially higher risk, particularly LQT2 in the postpartum period
- LQT1: generally lower risk when asymptomatic, QTc <500ms and on beta-blocker therapy
- LQT2: generally higher risk; event risk falls during pregnancy and is highest in the postpartum period (up to 12 months)^[5]
- LQT3, symptomatic LQTS, marked QTc prolongation, or an ICD: generally higher risk
Pregnancy-specific risks:
- LQT2: highest postpartum risk of the main genotypes. In 391 women in the LQTS Registry (all genotypes), cardiac event risk was lower during pregnancy (HR 0.28) and higher in the 9 months postpartum (HR 2.7) than before first conception, with LQT2 women most affected and beta-blockers protective postpartum (HR 0.34)^[11]
- LQT1: Generally lower risk during pregnancy (progesterone shortens QT), and postpartum risk is lower than in LQT2, but it is not eliminated, so continue beta-blockade and maintain surveillance
- LQT3: Intermediate risk; bradycardia during sleep may worsen arrhythmia substrate
Baseline assessment:
- 12-lead ECG with manual QTc calculation (Bazett formula acceptable)
- Exercise test (unmask QT behaviour, assess beta-blocker efficacy)
- Holter monitoring if palpitations/presyncope history
- Review ICD if present (programming, battery, lead integrity)
Medications:
- Beta-blockers: ESSENTIAL - do NOT stop (nadolol preferred for LQT1/LQT2; metoprolol acceptable)
- Mexiletine (LQT3): pregnancy data are limited; use only where clearly indicated, with specialist input and fetal monitoring
- Avoid ALL QT-prolonging drugs - check www.crediblemeds.org
Genetic counselling: each child has a 50% chance of inheriting the familial variant (autosomal dominant); whether and how severely disease develops depends on penetrance and variable expression; prenatal testing available

PREGNANCY MANAGEMENT:

Monitoring frequency:
- LQT2: Monthly cardiology review (high risk)
- LQT1/LQT3: Each trimester if stable and asymptomatic
- ECG each visit (monitor QTc evolution)
- Holter if palpitations, presyncope, or any symptoms
QTc evolution in pregnancy:
- Generally SHORTENS slightly in 2nd/3rd trimester (progesterone effect)
- BUT some LQT2 women have PARADOXICAL QTc prolongation
- Monitor closely if QTc increasing or >500ms
Beta-blocker management:
- DO NOT STOP - essential for arrhythmia prevention
- Nadolol 40-160mg/day (preferred, long half-life) OR metoprolol 100-200mg/day
- Monitor heart rate - target resting HR 60-70 bpm
- May need dose increase in pregnancy (increased drug metabolism)
Electrolyte management:
- Check potassium and magnesium each trimester
- Maintain K+ 4-5 mmol/L (supplement if <4.0)
- Supplement Mg2+ if levels low or if hyperemesis/frequent vomiting
Avoid triggers:
- QT-prolonging medications (antibiotics, antiemetics, antihistamines) - check ALL drugs
- LQT2 specific: Avoid sudden loud noises/alarms

LABOUR & DELIVERY:

Delivery planning:
- Deliver at tertiary centre (high-risk, especially LQT2)
- MDT planning ahead of expected delivery, timing individualized rather than fixed
- External defibrillator immediately available
Mode of delivery:
- Delivery mode is normally obstetric (vaginal delivery preferred if stable); an ICD in place is not by itself an indication for elective caesarean section
- Caesarean section may be considered for significant cardiac instability (e.g. recurrent syncope, very prolonged QTc) or standard obstetric indications, decided individually rather than by a fixed rule
- Assisted second stage to reduce sympathetic surge
Anaesthesia:
- Epidural generally preferred (reduces catecholamine surge from pain)
- Avoid QT-prolonging drugs: ondansetron carries a recognised QT-prolongation risk; metoclopramide and cyclizine are not established as electrically neutral alternatives either, check any antiemetic against a current QT-risk resource (e.g. CredibleMeds) and the BNF/SmPC, with pharmacy or anaesthetic input
- GA if needed: propofol generally considered compatible; avoid volatile anaesthetics (some prolong QT)
Intrapartum monitoring:
- Continuous ECG monitoring throughout labour
- Have IV magnesium sulphate available (torsades treatment)
- ICD: Reprogram if concerned about T-wave oversensing; keep magnet available
Continue beta-blockers THROUGHOUT labour - do not skip doses

POSTPARTUM - HIGHEST RISK PERIOD (ESPECIALLY LQT2):

Critical first 12 months postpartum (LQT2):
- Across LQTS, event risk about 2.7-fold higher in the 9 months postpartum than before first conception, with the greatest risk in LQT2^[11]
- Hormonal withdrawal (falling progesterone) → QT prolongation
- Sleep deprivation, emotional stress, fatigue
Immediate postpartum management:
- Monitor 24-48 hours postpartum (CCU/telemetry if LQT2)
- DO NOT STOP BETA-BLOCKERS - this is CRITICAL
- ECG on day 1 postpartum and at discharge (monitor QTc)
Outpatient monitoring (LQT2):
- Cardiology review individualized to risk, with a lower threshold for more frequent review through the first 12 months postpartum for LQT2
- ECG at each visit
- Holter if any palpitations/symptoms
- Patient education: Report immediately - palpitations, lightheadedness, syncope
Beta-blocker compliance:
- Counsel extensively about arrhythmia risk if stopped
- Continue same dose as pregnancy (or increase if QTc rising)
- Continue beta-blockade while breastfeeding; nadolol passes into breast milk in appreciable amounts and is renally cleared, so plan with the paediatric team and monitor the infant for bradycardia, hypotension and hypoglycaemia, especially if newborn or preterm
Sleep deprivation management:
- Particularly important for LQT3 (events during sleep)
- Encourage partner assistance with night feeds
Breastfeeding: generally encouraged; beta-blockers are usually continued, with infant monitoring (see above)
Contraception: individualise by formulation, genotype and beta-blocker use. Progestin-only oral contraceptives were associated with a 2.8-fold increase in cardiac events in women not taking beta-blockers (LQTS Registry, Goldenberg et al, Heart Rhythm 2022), especially LQT2, so they should not be used without beta-blockade

VERY HIGH-RISK SCENARIOS WARRANTING DETAILED MDT DISCUSSION:

Recurrent cardiac arrest despite beta-blockers and ICD
Recent electrical storm

These represent the highest-risk end of the spectrum and warrant individualized, detailed Pregnancy Heart Team discussion rather than being treated as an automatic bar to pregnancy.

GENOTYPE-SPECIFIC SUMMARY:

LQT1: Generally lower risk in pregnancy (progesterone protective); postpartum risk lower than LQT2 but not absent, continue beta-blockade
LQT2: highest postpartum risk; close monitoring through pregnancy and the 12 months postpartum
LQT3: Intermediate risk; sleep deprivation postpartum may increase events

Follow-up

Pragmatic surveillance approach informed by ESC 2022 Ventricular Arrhythmia guidelines (which do not mandate fixed monitoring intervals)^[1].

Advanced / complicated = prior cardiac arrest or syncope, markedly prolonged QTc, breakthrough events on therapy, or appropriate ICD therapy.

Genotype-positive / phenotype-negative (G+/P−) = a confirmed pathogenic-variant carrier with no overt disease expression yet.

	Genotype+ / Phenotype−	Uncomplicated / Stable	Advanced / Complicated
Frequency	Annual (concealed LQTS)	Annual	Every 6 months
Clinical review	Symptoms; QT-drug & adherence counselling	Symptoms, syncope, adherence, QT-drug review	As above + device check
ECG	Annual (QTc may be normal)	Annual 12-lead (QTc trend)	Each visit
Holter / ambulatory	As indicated	Periodic / symptom-directed	As indicated
Exercise / stress test	Consider (may unmask LQT1)	As indicated (paradoxical QT response, esp. LQT1)	As indicated
Echocardiography	Baseline	Baseline (exclude structural disease)	If symptoms change
Family screening	–	Cascade ECG ± genetic testing	–

Disclaimer: This table is general guidance based on published guidelines and does not replace clinical judgement. The responsible clinician is accountable for determining the appropriate, individualised follow-up plan for each patient.

Key Points

Normal QTc does NOT exclude LQTS if genotype-positive
Screen first-degree relatives with ECG and consider genetic testing if variant identified
Check www.crediblemeds.org before prescribing ANY medication^[1]
Do NOT stop beta-blockers abruptly (rebound tachycardia can be fatal)^[1]
Maintain K+ 4-5 mmol/L; replace promptly if low^[1]
Genotype guides triggers: LQT1 avoid competitive swimming; LQT2 avoid sudden loud noises
ICD does NOT replace beta-blocker therapy
LQT2: arrhythmic risk is not raised during pregnancy but rises in the postpartum period, up to 12 months (especially with prior symptoms); continue beta-blockers and maintain close follow-up for 12 months postpartum^[5]

References & Review Date

Last reviewed: October 2026

Key studies in LQTS · the landmark studies, drawn to scale with the other inherited cardiac conditions.

Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi:10.1093/eurheartj/ehac262
Schwartz PJ, Crotti L. Long QT syndrome. N Engl J Med. 2025;393:2023–2034. doi:10.1056/NEJMra2400853
Schwartz PJ, et al. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88(2):782–784. doi:10.1161/01.CIR.88.2.782
Abu-Zeitone A, et al. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014;64(13):1352–1358. doi:10.1016/j.jacc.2014.05.068
De Backer J, Haugaa KH, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462–4568. doi:10.1093/eurheartj/ehaf193
Joint Formulary Committee. British National Formulary (BNF). Nadolol. bnf.nice.org.uk/drugs/nadolol
Zhu W, Bian X, Lv J. From genes to clinical management: a comprehensive review of long QT syndrome pathogenesis and treatment. Heart Rhythm O2. 2024;5(8):573–586. doi:10.1016/j.hroo.2024.07.006
Asatryan B, Murray B, Gasperetti A, et al. Unraveling complexities in genetically elusive long QT syndrome. Circ Arrhythm Electrophysiol. 2024;17(2):e012356. doi:10.1161/CIRCEP.123.012356
Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348(19):1866–1874. doi:10.1056/NEJMoa022147
Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124(20):2187–2194. doi:10.1161/CIRCULATIONAHA.111.028258
Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49(10):1092–1098. doi:10.1016/j.jacc.2006.09.054
Kapplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6(9):1297–1303. doi:10.1016/j.hrthm.2009.05.021

Long QT Syndrome (LQTS)